Canada approves Moderna's RSV vaccine for those age 60 and older, company says
Moderna said on Friday Canada's health regulator has approved its vaccine for respiratory syncytial virus in adults 60 years ...
GSK to invest $800M in Pennsylvania drug expansion
The drugmaker’s U.S. expansion comes on the heels of a rough quarter, with lower vaccine demand driving down Q3 sales by 15% ...
Lethbridge Herald1d
Health Canada approves Moderna’s mRNA RSV vaccine, company says
There are two other vaccines already available in Canada to protect seniors against severe illness caused by RSV: Arexvy, ...
Canada approves Moderna's RSV vaccine for adults aged 60 and older
Moderna said on Friday Canada's health regulator has approved its vaccine for respiratory syncytial virus in adults 60 years ...
Canada approves Moderna’s RSV vaccine, first of its kind for older adults
Health Canada has approved the vaccine, mRESVIA, for the prevention of lower respiratory tract disease in older adults, the company said.
Pfizer, GSK, Moderna struggle in a shrinking RSV vaccine market
Q3 results confirms that the U.S. vaccine market for respiratory syncytial virus (RSV), led by Pfizer (PFE) and GSK (GSK), is ...
FiercePharma3d
AbbVie's Skyrizi rockets to top of TV drug ad spenders' list with single largest monthly total this year
AbbVie is reaching for the Sky(rizi) as it spent a staggering $51.5 million on TV drug ads for its immunology blockbuster in October. | AbbVie is reaching for the Sky(rizi) as it spent a staggering ...
The Pharma Letter3d
GSK’s Arexvy receives expanded approval in Canada
GSK’s Arexvy has received expanded approval in Canada for preventing RSV-related lower respiratory tract disease in adults ...
FiercePharma3d
Drugs for unmet needs and those from experienced companies had the best chance for successful launches in 2023: report
What’s an example of a well-executed drug launch? Look no further than Reata’s commercialization of Skyclarys, the first ...
GSK’s RSV vaccine approved in Canada for adults aged 50 to 59
GlaxoSmithKline (GSK) has received approval for its vaccine, AREXVY, in Canada to prevent lower respiratory tract disease ...
devdiscourse4d
Global Health Update: DiaSorin Leads Diagnostic Surge While RSV and Allulose Make Waves
This update in the health sector highlights major developments including DiaSorin's significant profit growth, GSK's RSV ...
Canada approves GSK's RSV vaccine for adults aged 50 to 59
GSK has received Canadian approval for its respiratory syncytial virus vaccine in adults between 50 and 59, the company said ...